Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Technical Presentation (June 2019)
17 slides from Corvus Pharmaceuticals's technical presentation, June 2019
Slide 1: Immunobiology, Preliminary Safety and Efficacy of CPI-006 in a Phase 1 Trial in Advanced Cancers
Immunobiology, Preliminary Safety and Efficacy of CPI-006, an Anti-CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers Jason J. Luke*, John D. Powderly II, Jaime R. Merchan, Minal A. Barve, Andrew N. Hotson, Mehrdad Mobasher, Long Kwei, Gabriel Luciano, Joseph J. Bu
Slide 2: Background
Background • Adenosine in the tumor microenvironment is Adenosine immunosuppressive AMP • CD73 is an ectoenzyme present on many tissues Ciforadenant including subsets of T and B cells CD73 – Converts AMP to adenosine – Functions in lymphocyte adhesion, migration and CPI-006 A2AR APCs activation* • C
Slide 3: CPI-006 Blocks CD73 Enzymatic Activity
CPI-006 Blocks CD73 Enzymatic Activity CD73 Catalytic Activity AMP → Adenosine + Phosphate CD73 IHC CD73 IHC (Non-Competitive Anti-CD73) (Competitive Anti-CD73) CD73 Enzyme activity* (absorbance 660 nm) 1.0 (absorbance 660 nm) 1.0 isotype isotype 0.8 0.8 CPI-006 CPI-006 phosphate phosphate 0.6 1mM 1
Slide 4: Immunomodulatory Activities of CPI-006 are Adenosine Independent
Immunomodulatory Activities of CPI-006 are Adenosine Independent Activation Markers Antigen Presentation CD69 CD83 CD25 CD86 MHC-II • Healthy donor PBMC treated overnight • Flow cytometry analysis of surface markers on B cells (CD19POSCD3NEG) • Lymphocyte markers are consistent with activation of B
Slide 5: Clinical Trial Design
Clinical Trial Design DOSE ESCALATION DOSE EXPANSION Design Arm 1a: CPI-006 • Phase 1/1b open label, 3 + 3 dose escalation/dose expansion 24 mg/kg • CPI-006 given as 1 hour IV infusion every 3 weeks; fixed dose 18 mg/kg 12 mg/kg of ciforadenant (100 mg po BID) for combo 6 mg/kg 3 mg/kg NSCLC Eligibi
Slide 6: Patient Characteristics
Patient Characteristics Baseline Demographics Description CPI-006 (N=12) CPI-006 + ciforadenant (N=8) Age (yrs), median (range) 62 (46, 78) 64 (36, 86) Gender, male n (%) 10 (83) 8 (100) No. of prior therapies, median (range) 4 (1, 5) 4 (3, 7) Histologies N N Bladder Cancer 1 0 Colorectal Cancer 2 2
Slide 7: Adverse Events
Adverse Events Adverse Events N(%) CPI-006 Monotherapy CPI-006 + Ciforadenant (N=12) (N=8) All Grades Grade 3 or 4 All Grades Grade 3 or 4 Subjects with any TEAE 8 ( 66.7) 1 ( 8.3) 5 ( 62.5) 0 ( 0.0) Anemia 1 ( 8.3) 1 ( 8.3) 1 ( 12.5) 0 ( 0.0) Diarrhea 1 ( 8.3) 0 ( 0.0) 1 ( 12.5) 0 ( 0.0) Nausea 3 (
Slide 8: Pharmacokinetics and Receptor Occupancy Data
Pharmacokinetics and Receptor Occupancy Data 3 Total Cell Free Cell 200 Surface CD73 Surface CD73 Serum Pharmacokinetics Peripheral CD8 150 Receptor Occupancy Percent 150 100 125 1000 CD73 Percent Occupancy 50 Serum CPI-006 (g/mL) 100 100 0 75 10 -50 50 1 25 • Exposure increases and clearance decre
Slide 9: Occupancy and Inhibition of CD73 in the Tumor
Occupancy and Inhibition of CD73 in the Tumor Non-Competitive Anti-CD73 Competitive Anti-CD73 CD73 Enzyme Activity Positive Control (Tonsil) 40x 40x 2x On-Treatment Bx • Colorectal patient treated with 12 mg/kg CPI-006 • Tumor biopsy demonstrates presence of CD73 which is occupied by CPI-006 • Tumor
Slide 10: Disease Assessment
Disease Assessment • Higher doses appear to be providing longer term disease control with monotherapy Cycle = 21 days Disease assessment every 3-4 cycles • Combination appears to improve disease control Jason J. Luke, MD 10
Slide 11: Treatment Induces Rapid Changes in PBMCs
Treatment Induces Rapid Changes in PBMCs CD73POS B cells Changes in PBMCs at 0.5 Hour 20190509 SA combo dots T cells monos• Consistent with Frequency * * * * Cell Frequency (Percentage of Lymphocytes) p < 0.0001 2.5 – Trafficking of CD73POS B cells out 1mg/kg 2.0 of the blood CD73POS B cells 3mg/kg
Slide 12: Changes in Blood B Cells Over Time
Changes in Blood B Cells Over Time Changes in CD73POS B cells Changes in HLA-DR Expression 6 mg/kg Monotherapy cohort HLA-DR ratio on B cells 2.0 Colorectal Normalized HLA-DR 1.8 CD73POS/CD73NEG SCC Head/Neck 1.6 Prostate 1.4 1.2 1.0 0.8 8 15 22 Days • CD73POS B cells drop with each infusion and par
Slide 13: Changes in CD73POS B Cells & Tumor Reduction in a Prostate Cancer Patient
Changes in CD73POS B Cells & Tumor Reduction in a Prostate Cancer Patient Changes in Circulating B Cells Pre-treatment Post cycle 2 • 72 year old man with widely metastatic prostate cancer; • Decrease in target lesion in patient receiving 6 mg/kg previous therapies include leuprolide/bicalutamide, m
Slide 14: Treatment Induces Cytokines Consistent with Immune Activation
olor Key Treatment Induces Cytokines Consistent with Immune Activation alue 1 2 Fold 3 change in Serum Analytes N=3, 6mg/kg Cohort 0.5 HR 2 HR 24 HR Day 8 Day 15 Day 22 Log2 Fold Change TNF-a TNF-α Color Key • Rapid induction of inflammatory cytokines TNF-b TNF-β MIP-1a MIP-1α • Subsequent induction
Slide 15: Proposed Model for CPI-006 Immunomodulatory Activity
Proposed Model for CPI-006 Immunomodulatory Activity Lymphoid tissue AMP Adenosine • Migration to and retention in lymph nodes. • Increased antigen presentation. CD73 CPI-006 BTK B cell CD69 Activation S1P1 ERK B cell Jason J. Luke, MD 15
Slide 16: Conclusions
Conclusions • CPI-006 has novel immunomodulatory activity with dual mechanisms of action: – Affects B cell trafficking and increases expression of CD69 and other markers consistent with increased antigen presentation by APCs – Complete inhibition of CD73 enzyme activity without internalization • CPI
Slide 17: Acknowledgements
Acknowledgements • The patients and their families • Participating Centers: Carolina BioOncology Institute, University of Chicago, Medical College of Wisconsin, Roswell Park Cancer Institute, Yale University, Mount Sinai, Icahn School of Medicine, Dana Farber Cancer Institute, Mary Crowley Cancer Ce
Corvus Pharmaceuticals — Technical Presentation (June 2019) on 6ix